Barclays analyst Emily Field took over coverage of Cytokinetics (CYTK) with an Overweight rating and $87 price target The firm expects Myqorzo to gain “dominant share” in the obstructive hypertrophic cardiomyopathy market and sees “a reasonable chance” of positive Phase ACACIA data in nHCM in Q2 of 2026, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- MYQORZO: EC Approval, Differentiated Label, and Global HCM Expansion Support Buy on CYTK
- Cytokinetics Wins European Approval for MYQORZO in HCM
- Cytokinetics announces EC has approved Myqorzo for oHCM in adults
- Cytokinetics: Buy Rating on Myqorzo’s oHCM Opportunity and 2026 Commercial Inflection Catalysts
- Cytokinetics price target raised to $92 from $84 at Truist